Plus Therapeutics, Inc. (PSTV)

Market Cap	22.85M +182.1%
Revenue (ttm)	5.21M -10.5%
Net Income	-22.39M
EPS	-7.25
Shares Out	6.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	552,328
Open	3.500
Previous Close	3.560
Day's Range	3.250 - 3.840
52-Week Range	3.225 - 30.500
Beta	1.02
Analysts	Strong Buy
Price Target	7.67 (+130.33%)
Earnings Date	Mar 12, 2026

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and sec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV
• Website: https://plustherapeutics.com

Financial Performance

In 2025, Plus Therapeutics's revenue was $5.21 million, a decrease of -10.49% compared to the previous year's $5.82 million. Losses were -$22.39 million, 72.5% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price target is $7.67, which is an increase of 130.33% from the latest price.

Price Target

$7.67

(130.33% upside)

Analyst Consensus: Strong Buy